Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (TAS-102 NEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04042714
Recruitment Status : Recruiting
First Posted : August 2, 2019
Last Update Posted : January 18, 2020
Taiho Oncology, Inc.
Information provided by (Responsible Party):
Baylor Research Institute

Brief Summary:
The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer. TAS-102 demonstrated improved survival and tolerability in patients with colorectal cancer and is currently approved by the FDA and marketed under the brand name Lonsurf for the treatment of patients with metastatic colorectal cancer (mCRC). Recently, a study evaluating TAS-102 showed a case of complete remission of high-grade NEC. Given the safety profile of TAS-102 and the remarkable single agent activity in a disease with otherwise dismal outcomes, we hope that TAS-102 may show tolerability and efficacy in neuro-endocrine cancer and propose further exploration in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer.

Condition or disease Intervention/treatment Phase
High-grade Extra Pulmonary Neuroendocrine Cancer Drug: All patients- TAS-102 Phase 2

Detailed Description:

Neuroendocrine tumors are highly prevalent cancer showing heterogeneous array of behaviors. For intermediate/high grade and poorly differentiated neuroendocrine carcinomas (NEC) that occur outside the lung, there is no acceptable standard of care. Most patients are treated with a platinum-based chemotherapy in the front-line setting and evidence for therapies in the second line setting is minimal representing a significant unmet need. However, the response rates have been unsatisfactory with progression-free survival of only 2.3 to 6.2 months, and there is an unmet need for an effective treatment for patients with refractory disease.

TAS-102 is a novel combination medicinal product consisting of a thymidine-based nucleoside analogue (trifluridine; FTD) as the active component and the thymidine phosphorylase inhibitor tipiracil hydrochloride (TPI) that has shown promising activity in phase I trials in patients with solid tumors and phase II in patients with gastric cancer. FTD enters cancer cells, interferes with DNA synthesis, inhibits cell proliferation and inhibit tumor growth. TPI helps FTD sustain its level in cells without degradation by thymidine phosphorylase (Tpase).Thus TAS-102 uses dual approach to inhibit rapid degradation of trifluridine and subsequent tumor growth.

Given the safety profile and efficacy, the study is designed to explore/evaluate efficacy of TAS-102 and identify characteristics of patients who may respond to this treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Patients with metastatic high-grade extra pulmonary NEC, who failed front line treatment with a platinum containing regimen, who meets the enrollment criteria will receive TAS-102 as a single agent until either progression or unacceptable toxicity.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase II Investigation of TAS-102 in Patients With High Grade, Extrapulmonary Neuroendocrine Carcinoma
Actual Study Start Date : August 15, 2019
Estimated Primary Completion Date : August 15, 2023
Estimated Study Completion Date : August 15, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TAS-102
Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
Drug: All patients- TAS-102
Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
Other Name: Trifluridine, Tipiracil

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 24 months ]
    To assess clinical activity [ORR = Partial response (PR)+Complete response (CR) ] of TAS-102 in patients with metastatic, extra pulmonary high grade NEC

Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: 24 months ]
    To assess OS in patients with metastatic extra pulmonary high grade NEC who received TAS-102 In comparison with historical records.

  2. Progression free survival (PFS) [ Time Frame: 24 months ]
    To assess PFS in patients with metastatic extra pulmonary high grade NEC who received TAS-102 in comparison with historical records

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologic confirmation of high grade NEC using WHO criteria as determined by Ki67>20%, poorly differentiated (G3) characteristics, or >20 mitotic figures/10 high-power fields.
  • Unknown primary may be included. Suspected extrapulmonary patients with known lung primary will be excluded.
  • Prior treatment with a platinum containing regimen
  • RECIST 1.1 measurable disease
  • Evidence of stage IV, metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  • Serum albumin ≥2.5 gm/dL.
  • Expected survival ≥3 months.
  • Adequate hematologic function as defined by: a) Absolute neutrophil count (ANC) >1500/mm3; b) Platelets ≥75,000/mm3; c) Hemoglobin >8 g/dL (in the absence of red blood transfusion).
  • Adequate liver function, as defined by: a) Serum total bilirubin ≤2.5 x ULN mg/dL. b) ALT (SGPT) and AST (SGOT) ≤5 x upper limit of normal (ULN).
  • Adequate renal function, as defined by serum creatinine ≤2.0 x ULN, or creatinine clearance ≥30 mL/min
  • Females of child bearing potential must agree to use contraception to avoid pregnancy throughout the study.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Evidence of low-grade or well-differentiated features as determined by the investigator.
  • Functional neuroendocrine tumors are excluded.
  • Known pulmonary primary or small cell lung cancer will be excluded.
  • Significant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.
  • Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38°C).
  • Other severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as: a) Severe impaired lung functions as defined by spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air, b) Uncontrolled diabetes,c) Liver disease such as cirrhosis or severe hepatic impairment, d) Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the integrity of the study.
  • Taking other investigational or anti-cancer treatments while participating in this study. Concurrent radiotherapy is allowed provided to non-target lesions. If target lesions have received radiation therapy, progression must have been demonstrated prior to enrollment.
  • Prior or concurrent malignancy, except for the following: a) Adequately treated basal cell or squamous cell skin cancer; b) Cervical carcinoma in situ; c) Adequately treated Stage I or II cancer from which the subject is currently in complete remission; d) Or any other cancer from which the subject has been disease-free for 3 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04042714

Layout table for location information
United States, Texas
Baylor Scott and White University Medical Center, Recruiting
Dallas, Texas, United States, 75246
Contact: Preethi Ravindranathan, MS    214-820-8685   
Contact: Silviya Meletath, MBBS    214-820-4987   
Principal Investigator: Scott Paulson, MD         
Sponsors and Collaborators
Baylor Research Institute
Taiho Oncology, Inc.
Layout table for additonal information
Responsible Party: Baylor Research Institute Identifier: NCT04042714    
Other Study ID Numbers: 019-075
019-075 ( Other Identifier: Baylor Scott and White Research Institute )
First Posted: August 2, 2019    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Neuroendocrine
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents